Saturday 17 October 2026
Export AURA’s income statement to Excel — free account
Aura Biosciences, Inc.
AURA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 2.13% and free cash flow fell 56.3%, each against the same quarter a year earlier.
6.10
0.24
−3.79%
Follow AURA
Aura Biosciences, Inc. (AURA) P/E ratio
Aura Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 1.1× (August 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 1.1×
Ten-year median
0.0×
Current reading's percentile
90
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| AVTX Avalo Therapeutics, Inc. compare | n/m |
| CADL Candel Therapeutics, Inc. compare | n/m |
| AURA Aura Biosciences, Inc. | n/m |
| GYRE Gyre Therapeutics, Inc. compare | n/m |
| DSGN Design Therapeutics, Inc. compare | n/m |
| ANNX Annexon, Inc. compare | n/m |
| PRME Prime Medicine, Inc. compare | n/m |
| PHAR Pharming Group N.V. Sponsored ADR compare | 62.4× |
| MDXG MiMedx Group, Inc compare | 111× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)